Molecular markers, molecular-targeted therapies and taxanes: How to integrate the progress into clinical research and practice for the management of head and neck cancers

Current Opinion in Oncology

Volumn 17, Issue 3, 2005, Pages 209-211

  Awada, Ahmad ^a   Lalami, Yassine ^a  

^a JULES BORDET INSTITUTE   (Belgium)

Author keywords

[No Author keywords available]

Indexed keywords

BEVACIZUMAB; CANERTINIB; CELECOXIB; CETUXIMAB; CISPLATIN; CYCLIN D1; DOCETAXEL; EPIDERMAL GROWTH FACTOR RECEPTOR; EPIDERMAL GROWTH FACTOR RECEPTOR KINASE INHIBITOR; ERLOTINIB; FAS ANTIGEN; FAS LIGAND; FLUOROURACIL; GEFITINIB; KI 67 ANTIGEN; LAPATINIB; MATRIX METALLOPROTEINASE; MATUZUMAB; METHOTREXATE; MOLECULAR MARKER; PANITUMUMAB; PLATINUM DERIVATIVE; PROSTAGLANDIN SYNTHASE INHIBITOR; PROTEIN BCL 2; PROTEIN P27; PROTEIN P53; SORAFENIB; SUNITINIB; TAXANE DERIVATIVE; TUMOR MARKER; UNINDEXED DRUG; VASCULOTROPIN;

CANCER CHEMOTHERAPY; CANCER GENETICS; CANCER RADIOTHERAPY; CANCER SURVIVAL; CLINICAL PROTOCOL; CLINICAL TRIAL; DIARRHEA; DISEASE MARKER; DRUG TARGETING; EDITORIAL; GENOMICS; HEAD AND NECK CANCER; HUMAN; HYPOPHARYNX CANCER; LARYNX TUMOR; META ANALYSIS; METASTASIS; NASOPHARYNX CARCINOMA; PRIORITY JOURNAL; PROTEOMICS; RASH; SQUAMOUS CELL CARCINOMA; STOMATITIS;

ANTINEOPLASTIC AGENTS; CARCINOMA, SQUAMOUS CELL; DRUG DELIVERY SYSTEMS; EVIDENCE-BASED MEDICINE; HEAD AND NECK NEOPLASMS; HUMANS; MEDICAL ONCOLOGY; NEOPLASM STAGING; TAXOIDS; TUMOR MARKERS, BIOLOGICAL;

EID: 17844386832     PISSN: 10408746     EISSN: None     Source Type: Journal    
DOI: 10.1097/01.cco.0000156984.81195.46     Document Type: Editorial

References (13)

1. Chin D, Boyle GM, Theile DR, et al. Molecular introduction to head and neck cancer (HNSCC) carcinogenesis. Br J Plast Surg 2004; 57:595-602.
2. Le Q-T, Giaccia AJ. Therapeutic exploitation of the physiological and molecular genetic alterations in head and neck cancer. Clin Cancer Res. 2003; 9:4287-4295.
3. Bonner JA, Giralt J, Harari PM, et al. Cetuximab prolongs survival in patients with locoregionally advanced squamous cell carcinoma of head and neck: A phase III study of high dose radiation with or without cetuximab. Proc. ASCO 2004, abstract 5607.
4. Licitra L, Vermorken JB. Is there still a role for neoadjuvant chemotherapy in head and neck cancer? Ann Oncol 2004; 15:7-11.
5. Lefebvre JL, Chevalier D, Luboinski B, et al. Is laryngeal preservation with induction chemotherapy safe in the treatment of hypopharyngeal SCC? Final results of thephase III EORTC 24981 trial. Proc. ASCO 2004, abstract 5531.
6. Vermorken JB, Remenar E, van Herpen C, et al. Standard cisplatin/infusional 5-fluorouacil (PF) vs docetaxel (T) plus PF (TPF) as neoadjuvant chemotherapy for nonresectable locally advanced squamous cell carcinoma of the head and neck: a phase III trial of the Head and Neck Cancer Group (EORTC 24971). Proc. ASCO 2004, abstract 5508.
7. Cohen E, Lingen MW, Vokes EE. The expanding role of chemotherapy in head and neck cancer. J Clin Orthod 2004; 22:1743-1752.
8. Wreesmann VB, Shi W, Thaler HT, et al. Identification of novel prognosticators of outcome in squamous cell carcinoma of the head and neck. J Clin Orthod 2004; 22:3965-3972.
9. Soulieres D, Senzer NN, Vokes EE, et al. Multicenter phase II study of Erlotinib, an oral epidermal growth factor receptor tyrosine kinase inhibitor, in patients with recurrent or metastatic squamous cell cancer of the head and neck. J Clin Orthod 2004; 22:77-85.
10. Trigo J, Hitt R, Koralewski P, et al. Cetuximab monotherapy is active in patients with platinum-refractory recurrent/metastatic squamous cell carcinoma of the head and neck (SCCHN): Results of a phase II study. Proc. ASCO 2004, abstract 5502.
11. Thomas SM, Grandis JR. Pharmacokinetic and pharmacodynamic properties of EGFR inhibitors under clinical investigation. Cancer Treat Rev 2004; 30:255-268.
12. Ataman OU, Bentzen SM, Wilson GD, et al. Molecular biomarkers and site of first recurrence after radiotherapy for head and neck cancer. Eur J Cancer 2004; 40:2734-2741.
13. Yoo GH, Piechocki MP, Ensley JF, et al. Docetaxel induced gene expression patterns in head and neck squamous cell carcinoma using cDNA microarray and power blot. Clin Cancer Res 2002; 8:3910-3921.